Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
Non-redox-active lipoate derivates disrupt cancer cell mitochondrial metabolism and are potent anticancer agents in vivo. [electronic resource] by
- Zachar, Zuzana
- Marecek, James
- Maturo, Claudia
- Gupta, Sunita
- Stuart, Shawn D
- Howell, Katy
- Schauble, Alexandra
- Lem, Joanna
- Piramzadian, Arin
- Karnik, Sameer
- Lee, King
- Rodriguez, Robert
- Shorr, Robert
- Bingham, Paul M
Producer: 20120202
In:
Journal of molecular medicine (Berlin, Germany) vol. 89
Availability: No items available.
|
|
8.
|
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. [electronic resource] by
- Alistar, Angela
- Morris, Bonny B
- Desnoyer, Rodwige
- Klepin, Heidi D
- Hosseinzadeh, Keyanoosh
- Clark, Clancy
- Cameron, Amy
- Leyendecker, John
- D'Agostino, Ralph
- Topaloglu, Umit
- Boteju, Lakmal W
- Boteju, Asela R
- Shorr, Rob
- Zachar, Zuzana
- Bingham, Paul M
- Ahmed, Tamjeed
- Crane, Sandrine
- Shah, Riddhishkumar
- Migliano, John J
- Pardee, Timothy S
- Miller, Lance
- Hawkins, Gregory
- Jin, Guangxu
- Zhang, Wei
- Pasche, Boris
Producer: 20170824
In:
The Lancet. Oncology vol. 18
Availability: No items available.
|